T o modulate an immune response against autoantigens, most studies apply an immunomodulatory reagent systemically or target it to the site of the autoimmune inflammation. As the initiation of an immune response might occur mainly in regional lymph nodes and other secondary lymphoid organs, 1 this compartment of the immune system might be an ideal target to modify the response in an initial stage.
Interleukin-4 (IL-4) is a cytokine that plays a key role as a mediator of T helper 2 type T-cell responses, [2] [3] [4] [5] and has been reported to influence T helper 1-mediated autoimmune diseases such as collagen-induced arthritis in mice 6 and experimental autoimmune encephalomyelitis in rats. 7 Furthermore, IL-4 stimulates the generation of CD8 ϩ T lymphocytes 8 and has been studied in clinical trials as an antitumor therapy. 9 Because IL-4 has a short half-life in circulation, 9 the use of cell-mediated gene therapy to boost the on-site release of recombinant IL-4 (rIL-4) might be a logical strategy.
We have evaluated two bone marrow-derived cell types, dendritic cells (DC) and hematopoietic stem cells (HSC), as vehicles for the delivery of rIL-4 in a syngeneic mouse model. DC are differentiated, professional antigen (Ag)-presenting cells and have a high migratory capacity. When they are injected subcutaneously (s.c.), they migrate to the regional lymph nodes in the drainage area. 10 Therefore, genetically engineered DC could function as vehicles to deliver a transgene product to the local lymph nodes. The pluripotent HSC are located primarily in the bone marrow and, by proliferation and differentiation, produce all of the mature lineages, including lymphocytes. The latter then populate the lymphoid organs. Therefore, transduced HSC can also be used to deliver a transgene systemically to all immunocompetent tissues where bone marrow-derived cells are found.
To determine the feasibility of tissue-directed delivery of an immunomodulatory cytokine gene, we have studied the efficiency of transduction of DC and HSC with vectors carrying the IL-4 gene and the distribution of the transduced cells in a mouse model.
MATERIALS AND METHODS

Retroviral vectors
Two retroviral vectors, both carrying the murine IL-4 (mIL-4) gene 11 and the selection marker gene neomycin phosphotransferase gene (neo), 12, 13 were used. Both vectors were tested for each cell type, and the one with the better transduction efficiency was used for further experiments (data not shown).
HSC were transduced with the MBAE-mIL-4 neo vector (kindly provided by N. Hozumi, Toronto, Canada), which consists of mIL-4 DNA 11 that was inserted into the HindIII site of the retroviral vector MBAE.
14,15 DC were transduced with the pBABE-mIL-4 neo vector (generously provided by Y. Chernajovsky and H. Land, London, UK), which consists of mIL-4 DNA inserted into the BamHI site of the pBABE neo retroviral vector. 16 
Culture and transduction of murine DC in transwell plates
Bone marrow cells were cultured in the lower chamber of transwell plates (Costar, Cambridge, Mass) and separated by a 0.4-m semipermeable membrane from retrovirus producing GPϩE86 packaging cells in the upper chamber of the plate in Dulbecco's modified Eagle's medium with 20% fetal calf serum. A total of 100 ng/mL polybrene (Sigma, St. Louis, Mo), 25 ng/mL stem cell factor (SCF), 5 ng/mL granulocyte-macrophage colony stimulating factor (GM-CSF), 500 U/mL IL-4, and 100 U/mL tumor necrosis factor-␣ (TNF-␣) (all cytokines from Biosource, Germany) were added to the medium. The nonadherent cells were removed by daily exchange of half of the medium and supplementation with new medium during the first 4 days of culture. After 7 days, the cells showed a typical DC morphology ( Fig 1A) and were removed from the plate with a cell scraper. Aliquots of the harvested DC were analyzed by fluorescence-activated cell sorter (FACS) staining, and others were used for the experiments. No G418 selection of transduced cells was performed for this experiment.
Injection of transduced DC into mice
A total of 1 ϫ 10 6 syngeneic DC in 50 L of phosphatebuffered saline were injected s.c. into the front limbs of DBA/1 mice. After 3 days the mice were sacrificed, the axillary lymph nodes were removed, and the DNA was extracted from a single-cell suspension of the lymph nodes.
FACS staining of DC
To measure the purity of the DC culture, the transduced DC were stained with the following anti-murine antibodies (Abs): M1/70 (anti-CD11b fluorescein isothiocyanate (FITC)), rmC5-3 (anti-CD14 FITC), 30F11.1 (anti-CD45 FITC), KH116 (anti-I-Aq) (all from PharMingen, Hamburg, Germany), OKT3 (anti-CD3 FITC) (Biosource), NLDC 145 (an anti-murine DC-specific marker) (Serotec, Germany), or isotype-matched control Abs (Immunotech, Germany). The binding of the unconjugated Abs was detected by incubation with conjugated Abs specifically binding to mouse immunoglobulin G2b (for KH116) and rat immunoglobulin G2a (for NLDC 145) (Immunotech). FACS analysis was performed using a FACScan (Becton Dickinson, Mountain View, Calif).
Transduction of murine HSC
We treated 8-to 12-week-old male DBA/1 mice with 5-fluoruracil (5-FU) (150 mg/kg body weight), which was injected intraperitoneally 6 days before the mice were killed. Bone marrow was harvested from the 5-FU-treated mice by flushing the cavities of femurs, tibiae, and humeri with medium. The bone marrow cells (2 ϫ 10 6 cells/6-cm Petri dish) were incubated for 48 hours in Petri dishes and cocultured with irradiated GPϩE86 packaging cells carrying the retroviral vectors. To increase transduction efficiency, 6 mg/mL polybrene (Sigma), 100 ng/mL recombinant murine SCF, 20 ng/mL IL-3, 15 ng/mL IL-6, and 1 ng/mL GM-CSF (all cytokines from Biosource) were added to the culture medium. The nonadherent bone marrow cells were harvested by flushing the GPϩE86 monolayer several times with medium. The viability of the cells was examined by trypan blue exclusion.
Measurement of the transduction efficiency and rIL-4 release of HSC
A total of 4.5 ϫ 10 4 transduced bone marrow cells were added to 300 L of growth factor-supplemented methylcellulose medium (Stem Cell Technologies). The medium was then placed in 3-cm Petri dishes (Stem Cell Technologies). To allow the integration of the recombinant genes, the dishes were incubated for 2 days without G418. A total of 1 mg/mL G418 (geneticin) (Life Technologies, Gaithersburg, Md) was then added to the culture, and all dishes were vigorously mixed with a pipette tip. After 8 days of culture, G418-resistant colonyforming units (CFU) were counted under an inverted microscope. To measure the IL-4 release of the transduced clones, the colonies were harvested after 8 days of culture, washed several times to remove the methylcellulose medium, and placed in Dulbecco's modified Eagle's medium at a cell density of 1 ϫ 10 6 cells/mL. The medium contained the same cocktail of hematopoietic growth factors that we used in the transduction experiments. After 48 hours, the supernatant was harvested and the IL-4 concentrations were analyzed by enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's instructions (R&D Systems, Wiesbaden, Germany).
Bone marrow transplantation (BMT)
Female DBA/1 mice were irradiated with 9 Gy. Transduced bone marrow cells of male, 5-FU-treated DBA/1 mice were harvested, and 2 ϫ 10 6 cells/mouse were administered intravenously (i.v.) in 100 L of phosphate-buffered saline into the tail vein of the irradiated female mice. The mice were sacrificed after 10, 13, or 39 days, and their organs were removed for DNA extraction. As controls, irradiated GPϩE86 packaging cells were injected, and control organs were analyzed similarly to those for the bone marrow-transplanted mice.
Generation of a deleted internal standard for quantitative polymerase chain reaction (PCR)
To quantify the number of proviral neo gene copies, we established a quantitative competitive PCR assay using a deleted internal standard. The internal standard is a 103-bpdeleted copy of the wild-type (wt) neo gene and was designed by overlap extension. 17 The Neo DNA sequences flanking the 103-bp region to be deleted were amplified in two separate reactions: DNA bases 831-1206 of the neo gene were amplified with primers neo831 (5Ј-AAGAGACAGGATGAAGGAT-CG-3Ј) and neo1206 (5Ј-GCCATGATGGATACTTTCT-3Ј). DNA bases 1309 -1650 of the neo gene were amplified with primers neo1309 (5Ј-AAGTATCCATCATGGCCTTGTC-GATCAGGATGAT-3Ј) and neo1650 (5Ј-CAGAAGAACTC-GTCAAGA-3Ј). Amplification conditions were as follows: 4 minutes of initial denaturation, 36 cycles of denaturation for 30 seconds at 94°C, 1 minute annealing at 55°C, and 1.5 minutes of extension at 72°C, followed by a final extension of 10 minutes at 72°C. As the primer neo1309 was designed to be partially complementary to neo1206 at the 5Ј end, mixing and denaturation/renaturation of the PCR products led to spontaneous formation of a hybrid molecule consisting of the two amplificates called neo-del (Fig 1B) . Neo-del was amplified with primers neo831 and neo1650 under the same PCR condi-tions as described above. Correct adaptation of fragments was confirmed by DNA sequencing using an automated sequencer (ALF-express; Pharmacia, Freiburg, Germany) and the femtomole cycle sequencing kit (Promega, Mannheim, Germany).
The copy number of neo-del after amplification was calculated from the DNA concentration determined by ultraviolet (UV) spectrophotometry and the molar weight of neo-del (1434 bases, 330 mol per base). 
Qualitative and quantitative PCR for the neomycin phosphotransferase gene (neo)
The neo gene was amplified from 200 ng of genomic DNA in a nested PCR using primers neo831 and neo1650 during the first PCR and primers neo931 (5Ј-ACAAACAGACAATCG-GCTGCT-3Ј) and neo1527 (5Ј-GCCAACGCTATGTCCT-GATA-3Ј) during the second PCR. Amplification was performed in a total volume of 50 L containing 20 mM deoxynucleoside triphosphates (Pharmacia), 5 L of 10ϫ reaction buffer A (AGS, Heidelberg, Germany), 20 pmol of each primer, and 2 L of Taq polymerase (AGS). Amplification conditions were the same as described above, except for an annealing temperature of 60°C. The PCR products from the first PCR were diluted 1/100 before being subjected to a second PCR. PCR products were visualized after electrophoresis on ethidium bromide (EB)-stained 2% agarose gels under UV light (size of specific PCR product: 597 bp). Those samples that were positive for qualitative PCR were subjected to a nested quantitative PCR for the neo gene: 200 ng of sample DNA were coamplified with 10-fold neo-del (deleted internal standard) dilutions (same PCR conditions as described above), and resulting PCR products (494 bp for neo-del, 597 bp for neo wt) were compared after 2% agarose gel electrophoresis and EB staining under UV light (Fig 2) . The copy number of neo in the sample was determined by comparison of the band size of wt neo and internal standard (neo-del). In most cases, a second-step amplification with smaller dilution steps was performed to allow a more exact determination of copy number.
Preparation of DNA samples
DNA was extracted from cell suspensions of mice organs with a QIAamp DNA-kit (Qiagen, Hilden, Germany) following the manufacturer's instructions.
PCR for the sry gene
Engraftment of transplanted male bone marrow cells was confirmed by PCR for the sry gene, which is specific for the murine Y-chromosome. 18 DNA was extracted from bone marrow samples at day 39 after BMT. The following sryspecific primers were used: sryA (5Ј-CAGCCCTACAGCCA-CAT-3Ј) and sryB (5Ј-CCACTCCTCTGTGACACTTT-3Ј).
PCR products were visualized after electrophoresis in EBstained gels under UV light.
RESULTS
Culture and transduction of DC After 7 days of culture in the presence of GM-CSF, SCF, IL-4, and TNF-␣, a high proportion of the transduced murine bone marrow cells showed typical DC morphology ( Fig 1A) . The cells highly expressed major histocompatibility complex class II and CD11b and strongly bound the Ab NLDC 145; the latter recognized a specific marker for DC 19 ( Fig 1B) . CD14 was only weakly expressed, and CD3 was negative. This pattern of surface molecule expression is characteristic for mature DC and is thought to be specifically induced by the presence of GM-CSF and IL-4. 20 When the transduced DC were washed and grown in culture for 48 hours, IL-4 could be detected in the supernatant at a concentration of 170 Ϯ 30 (SD) pg/mL in three consecutive experiments. Untransduced DC, which were cultured under the same conditions, showed the same characteristics but did not release any detectable IL-4. Quantitative PCR for the selection marker gene neo was performed with RNA from transduced cells. A total of 100 -500 gene copies of neo per 5000 cells were detected in six subsequent experiments, corresponding to an estimated transduction efficiency of 2-10% for DC.
Migration of transduced DC to regional lymph nodes after s.c. injection At 3 days after transduced syngeneic DC were injected into the right front limb, the axillary lymph nodes were removed. In DNA extracted from the right axillary lymph nodes, neo as a marker for transduced cells was detectable by PCR (Fig 3A) . In contrast, the contralateral left axillary lymph nodes showed no detectable neo (Fig 3A) , nor did the liver, thymus, spleen and mesenterial lymph nodes (data not shown). This results could be confirmed by four subsequent experiments. We then performed a kinetic analysis of the transduced DC migration to the lymph nodes (Fig 3B) . The transduced DC were not present in the axillary lymph nodes at day 1 after injection into the limb. At days 3 and 5, strong bands for neo show the presence of the DC in the lymph nodes. At day 7, neo was again nondetectable, indicating the disappearance of the transduced DC from the axillary lymph nodes.
HSC transduction HSC could be transduced with an efficiency of 17-33%, as demonstrated by G418-resistant growth of CFU in methylcellulose medium (Table 1) . Control wells with untransduced cells showed no growth in G418-containing medium. When the transduced clones were harvested from G418-containing methylcellulose medium and were further cultured in suspension for 48 hours, 1 ϫ 10 6 cells/mL released 55-104 pg/mL IL-4 into the supernatant (Table 1) . Nontransduced cells grown in the absence of G418 produced Ͻ20 pg/mL IL-4 (data not shown). When the DNA of the G418-resistant clones was analyzed by PCR for the presence of neo as a marker gene for transduced cells, a strong band was visible, confirming the presence of the transduced genes in the G418-resistant colonies (data not shown).
BMT with retrovirally transduced hematopoietic cells
In two consecutive experiments, each with 12 mice subject to lethal irradiation, 2 ϫ 10 6 transduced syngenic bone marrow cells were transplanted. However, as the transduced cells were not selected by the presence of G418, the transplanted cell population did not consist of 100% transduced cells. Mice were sacrificed after 10 (expt. 1), 13, and 39 (expt. 2) days, and bone marrow, spleen, thymus, liver, and mesenterial lymph nodes were analyzed for the presence of neo as a marker gene. The analysis was performed quantitatively with a competitive PCR technique using a 103 bp-deleted internal standard. After 10 and 13 days, neo could be detected in at least one of the analyzed organs in every mouse ( Table 2 ). The distribution of the transduced cells in the analyzed organs showed a wide variation among the mice. In some mice, Ͼ100 gene copies could be found in 200 ng of DNA (approximate DNA yield of 5 ϫ 10 3 cells) from an organ (for example 703 gene copies in the thymus in expt. 1, mouse no. 2) ( Table 2 ). In other organs of the same mouse or in the same organ in other mice, no detectable neo was found. Moreover, in expt. 1 increased amounts of neo were found in the liver and spleen compared with expt. 2. This might be explained by a 4 transduced bone marrow cells in growth factor-supplemented methylcellulose medium in either the presence or absence of G418. In expt. 1 and expt. 2, the cell population was also used for transplantation of irradiated syngenic mice (Table 2 ). In expt. 2 the overall colonyforming capacity (725 colonies per 4.5 ϫ 10 4 cells) was higher compared with expt. 1 (352 colonies per 4.5 ϫ 10 4 cells). †No colonies were seen when untransduced stem cells were cultured in the presence of G418.
‡IL-4 was measured by ELISA in the supernatant of 1 ϫ 10 6 /mL G418-resistant colony-forming cells. Nontransduced colony-forming cells released [H]20 pg/mL IL-4.
§ND, not determined.
decreased overall colony-forming capacity of the cells in expt. 1 (Table 1) , which might have resulted in increased entrapment of nonviable cells in liver and spleen. However, the surveillance of cell viability with trypan blue exclusion before the transplantation of the cells showed no difference in both experiments. In the three mice analyzed at day 39, neo could be detected in one mouse only. In contrast, sry was found in all organs of the mice sacrificed at day 39. This indicated that the male donor bone marrow cells transplanted into the female host mice did engraft, and that the transgene was probably nondetectable in some subjects at day 39.
DISCUSSION
In this study, we have demonstrated that in a syngeneic murine model, IL-4-transduced DC migrated to regional lymph nodes when they were administered s.c. DC derived from murine bone marrow were transduced with a retroviral vector, and the transgene product IL-4 was unequivocally expressed. Successful transduction of human 21 and murine [22] [23] [24] [25] [26] DC with retroviral vectors was well known. Neo as a marker for transduced DC was detectable in the lymph nodes on days 3-5 but was at nondetectable levels on day 7 after administration. Therefore, we concluded that the transduced DC migrated to the regional lymph nodes in a similar kinetic shown for untransduced DC before. 10 This migratory potency of DC is well characterized in particular for Langerhans DC of the skin. These professional Agpresenting cells have the ability to migrate out of the epidermis to the afferent lymphatics and reach the local lymph nodes, where they become part of the "interdigitating cells" of the T-dependent areas. This movement of Langerhans DC, which is accompanied by a process of maturation of the cells, is thought to be critical for carrying Ag and for inducing a primary T-cell response. 1 Lymph node-specific migration was not found in DC that had been administered i.v., which accumulated mainly in the spleen. 10 Hence, we have demonstrated that DC transfected with a retroviral vector for IL-4 could be targeted to the regional lymph nodes in the vicinity of the affected organs and might therefore deliver IL-4 as a recombinant immunomodulatory cytokine to the lymph node. In addition to its potential use in autoimmune diseases, transduced DC might be useful as an adjuvant in vaccination or anticancer therapy. The simultaneous presence of s.c. injected Ags and genetically modified cytokine-producing DC in regional lymph nodes might either enhance or modulate the immune response. 25, 26 As an alternative vehicle, we studied HSC as vehicles for the rIL-4 gene to lymphoid organs. HSC were transduced with IL-4 by coculture with irradiated packaging cell lines producing the retroviral vector, which contains the gene for IL-4 and the neomycin resistance gene neo. As the neo gene has to be integrated into the HSC genome first, no G418 selection was performed during the 48-hour coculture period. Therefore, the transplanted HSC population consisted of only 22% transduced cells in expt. 1 and 17% in expt. 2, respectively (Table 1) . Although all mice received the same conditioning regimen, they showed a wide range of heterogeneity in engraftment of the transduced cells. For example, the rate of detection of transduced cells in the spleen after 10 and 13 days, respectively, ranged from four of five in expt. 1 to zero of four in expt. 2; in the liver, the rate of detection ranged from two of five in expt. 1 to zero of four in expt. 2. This increased appearance of neo in the liver and spleen in expt. 1 might be related to the diminished overall colony-forming 
Data are reported as neo copies per diploid genome: Ϫ ϭ 0; ϩ ϭ 0.001-0.01; ϩϩ ϭ 0.01-0.1; ϩϩϩ ϭ Ͼ0.1 (neo copies per diploid genome).
The increased detection of neo in the liver and spleen in expt. 1 might be related to decreased colony-forming capacity (Table 1 ) and therefore increased entrapment of transduced cells in the liver and spleen.
capacity of the cells that we observed in expt. 1 (352 colonies per 4.5 ϫ 10 4 cells) compared with expt. 2 (725 colonies per 4.5 ϫ 10 4 cells) ( Table 1 ). The transduced cell population of expt. 1 might have had a decreased capacity for long-term survival, which might have resulted in increased entrapment of the cells in the liver and spleen. However, surveillance of cell viability with trypan blue exclusion before the cell transplantation showed no difference in both experiments. Possible further explanations for heterogeneity in transduced cell distribution include: trapping of a variable proportion of the cells in the lung after i.v. injection, rapid elimination of the transgene, immunological reactions of the host against viral proteins of the vector, influences of the transgene product itself on migratory behavior, and rejection of transduced cells. These factors might influence the engraftment and the distribution of the transduced cells to the lymphoid organs. As we could detect the sry gene in all organ samples 39 days after transplantation in expt. 2, it is unlikely that our conditioning regimen resulted in insufficient engraftment of the donor cell population.
The disappearance of the transduced cells might be a result of an immunological reaction of the host against a retroviral protein such as the neo gene product expressed on the transduced cells. However, in contrast to adenoviral vectors, 27 immunological rejection of cells transduced with retroviral vectors in gene therapy has not been shown to be a major problem. The release of IL-4 by the transduced cells in our system might contribute to the rejection, as IL-4 was shown to stimulate the generation of potential antiviral CD8 ϩ T lymphocytes. 8 In addition to its immunoregulatory properties, IL-4 has direct and indirect effects on the growth of hematopoietic cells. IL-4 costimulates the growth of CFU of hematopoietic cells in soft agar. 28 However, in the presence of bone marrow stromal cells, IL-4 induces a soluble factor that has been reported to inhibit the growth of hematopoietic cells. 29 As the transduced hematopoietic cells in our experiments produce rIL-4, this paradoxical effect of IL-4 on hematopoietic cell growth might contribute to our findings that the transduced cells grow very well in soft agar, but can be found only partially in bone marrow transplanted mice. The results of our experiments are partially consistent with the results of Chambers et al, 15 both showing migration of IL-4-transduced HSC to lymphoid organs. However, we could not confirm the long-term presence of transduced cells in our experiments. This could be due to the use of a different mouse strain. Although the exact mechanism is unclear, the wide variability in the longterm presence of retrovirally transduced HSC in lymphoid organs might be a major problem for the use of HSC as vehicles to deliver desirable transgenes to lymphoid organs. The use of other immunomodulatory proteins such as cytokine antagonists as therapeutic gene products might be different, as such molecules do not demonstrate an immunostimulatory potency.
Although this study was not designed to investigate the in vivo release of the transgene product IL-4 by the transplanted cells, we performed reverse transcriptase-PCR for IL-4 RNA and ELISA measurements of IL-4 protein from cell suspensions recovered from the various organs and from bone marrow. We could detect IL-4 RNA and protein in a majority of the investigated samples. However, there was a wide variation in inherent IL-4 release in untreated mice, making it difficult to differentiate between rIL-4 and naturally expressed IL-4.
In conclusion, bone marrow cells can be genetically modified to produce rIL-4. When the cells are differentiated in vitro to DC, our experiments have demonstrated that they can be used as mediators to deliver transgenes to regional lymph nodes. Genetically modified DC might therefore be a potential adjuvant for immune modulation in the therapy of localized autoimmune diseases, although HSC could also be used to deliver transgenes to lymphoid organs. However, the wide variability in the distribution of the transduced cells and their progeny cells might limit its potential with IL-4 as a transgene.
